Two breast PDO studies pair antibody/nanobody distribution with ADC-associated morphology and viability to guide imaging, dose design and efficacy comparisons.
STUDY EVIDENCE
Breast cancer PDO studies combine frozen-section distribution of labeled antibody/nanobody formats with post-ADC morphology and dose response to inform molecular format, imaging conditions and candidate evaluation.
Bright-field, DAPI, AF549 and merged views show the relative distribution of labeled molecules in PDO sections.
Guides refinement of molecular format, timing and imaging endpoints
Bright-field views under control, 0.3 μM and 3.0 μM conditions provide morphological context for viability readouts.
Pairs morphological change with quantitative viability readouts
The curves show different viability profiles across a candidate ADC concentration range in two PDO models, with replication and statistical analysis supporting dose-window selection and follow-on candidate comparison.
Compares model-level response differences and informs follow-on sample studiesINTERPRETATION
Plan ADC imaging, dose selection and candidate comparisons using labeled-antibody/nanobody distribution and ADC activity readouts.
For a new ADC program, spatial imaging and activity testing can be combined in one study to connect target expression, tissue distribution and response.
Evaluate target profiling, competition controls and time-course imaging alongside apoptosis and independent-sample results.
Related models and services
PROJECT DISCUSSION
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.
Two breast PDO studies pair antibody/nanobody distribution with ADC-associated morphology and viability to guide imaging, dose design and efficacy comparisons.
STUDY EVIDENCE
Breast cancer PDO studies combine frozen-section distribution of labeled antibody/nanobody formats with post-ADC morphology and dose response to inform molecular format, imaging conditions and candidate evaluation.
Bright-field, DAPI, AF549 and merged views show the relative distribution of labeled molecules in PDO sections.
Guides refinement of molecular format, timing and imaging endpointsBright-field views under control, 0.3 μM and 3.0 μM conditions provide morphological context for viability readouts.
Pairs morphological change with quantitative viability readoutsThe curves show different viability profiles across a candidate ADC concentration range in two PDO models, with replication and statistical analysis supporting dose-window selection and follow-on candidate comparison.
Compares model-level response differences and informs follow-on sample studiesINTERPRETATION
Plan ADC imaging, dose selection and candidate comparisons using labeled-antibody/nanobody distribution and ADC activity readouts.
For a new ADC program, spatial imaging and activity testing can be combined in one study to connect target expression, tissue distribution and response.
Evaluate target profiling, competition controls and time-course imaging alongside apoptosis and independent-sample results.
Related models and services
PROJECT DISCUSSION
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.
